GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva.

A 201-level at how GLP-1 drugs lead to appetite reduction

It's well-established that drugs which mimic the hormone GLP-1 can help people lose weight and control blood sugar levels, primarily through appetite reduction. This technical review provides an overview of how both natural and therapeutic GLP-1 interacts with the gut and brain to produce its effects.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for)

Glucagon-like peptide-1, or GLP-1, is one of the most well-known peptides in common use. In 2024, 26.5% of all adults with diagnosed diabetes used the substance. GLP-1 was particularly popular among people with diabetes aged 50-64, followed by younger adults and then seniors aged 65+.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

GLP-1 drugs mimic a natural hormone that triggers appetite-suppressing effects

Ozempic, one of the brand names for the drug semaglutide, was originally developed in 2012, to help treat Type 2 diabetes. Among other effects, the drug mimics a naturally produced hormone known as GLP-1, which is released while eating to let our bodies know we are full.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

GLP-1 helps reduce obesity through a number of mechanisms

Clinical studies show GLP-1 drugs, including semaglutide, promote weight loss through a number of effects. These include reduced appetite, slower emptying of the digestive tract, increased insulin production, and more.

Semaglutides, which belong to a class of drugs called GLP-1s, are prescribed for weight loss in combination with diet and exercise because they trigger the release of the appetite-suppressing hormone incretin.

GLP-1s are netting interest for treating autoimmune diseases, but are considered experimental

Already used to treat type 2 diabetes, the novel medications are showing some early promise in experimental studies at reducing inflammation and treating autoimmune conditions including rheumatoid arthritis and inflammatory bowel conditions. But researchers caution that side effects are still under investigation—rarely the medication has caused lupus, an autoimmune disease.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Debunking myths about weight loss drugs

Business Insider delves into the research on GLP-1 to highlight the good and bad aspects other stories overlook. Few make it clear that GLP-1 drugs simply don’t work for many people. This deep dive raises a number of questions about the future of GLP-1 and how they will be used.

Read the FDA's statement on concerns over compound pharmacies

GLP-1 drugs popularity for weight loss and treating diabetes, led to a significant supply shortage and the rise of compound pharmacies, which produce customized drug formulations but lack formal approval from regulators. The drugs are ostensibly the same, but manufacturing methods lead to variations in concentration, filler compounds, and more.

When people stopped using GLP-1, they regained two-thirds of the weight back

Research from 2022 found that when people stopped using the injectable form of the medication, they regained up to two-thirds of lost weight within a year. The finding suggests ongoing treatment will be required for weight loss.

What do people do once GLP-1 medications succeed at weight loss?

The drugs have been adopted by 1 in 8 Americans, with many achieving their prescribed weight loss. They now face the question of how to keep the weight off, the key issue with any weight loss program that researchers have known about for decades. Each case is unique. Some folks continue to use GLP-1s like Ozempic in minuscule doses, while others taper them off over time.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

Risks of GLP-1s include health side effects, counterfeit drugs, and more

This episode interviews researchers and patients who have used semaglutide to explore some of the potential risks associated with using the drug to lose weight. These include insurance challenges, health scares related to counterfeit versions of these drugs, and some users lose their ability to enjoy food.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

12% of adults were taking injectable GLP-1 for weight loss according to 2025 survey

Weight loss injectable use rose sharply between 2024 and fall 2025. The percentage of adults who reported taking this class of medicine specifically for weight loss increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

GLP-1s may lower inflammation, possibly helping to combat cognitive decline

An analysis of existing GLP-1 research, published in April 2025, indicated that GLP-1 drugs reduce inflammation, with numerous health benefits. The work notes that GLP-1s were linked with a statistically significant reduction in dementia in randomized clinical trials.

Tirzepatide: A GLP-1 drug that also acts on separate receptors to promote weight loss

Tirzepatide, like semaglutide, is a GLP-1 drug used in diabetes treatment and for weight loss. Unlike semaglutide, it also acts on glucose-dependent insulinotropic polypeptide receptors, proving a second route to reducing appetite as a means to treat diabetes and promote weight loss.

Medicare does not pay for GLP-1 for obesity

Coverage for GLP-1s for obesity treatment is limited. It's barred under Medicare, and it's only covered under Medicaid in 13 states as of January 2026, since states can choose whether to cover weight-loss drugs under Medicaid. Coverage with private insurers also remains limited.

How semaglutides are both better and worse than we know

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.

Not everyone who is a candidate for GLP-1 is choosing to use the drug

One person writes about why, although she's a good fit for the medication on paper, she's decided not to take GLP-1 due to concerns about mental health and other side effects, among other reasons.

Can you microdose GLP-1 agonists like Ozempic?

GLP-1 agonists like Ozempic can help with weight loss, diabetes, and anti-inflammation. For some users, normal doses are too much. So, they've started "microdosing"—taking a smaller amount than the lowest increment of the drug available. While not yet backed by clinical trials, some doctors observed positive effects for certain people.

Snake venoms are repurposed proteins responsible for other bodily functions

Just as saliva aids digestion in humans, proteins responsible for bioactivities such as digestion and blood clotting were eventually secreted in the glands and fangs of snakes across evolutionary history. Organisms that could not withstand the effects of these molecules (e.g., excessive bloodstream clotting) became ideal prey for snakes.

Companies developing new weight loss drugs

In recent years, weight loss drugs made a tremendous amount of money for Novo Nordisk and Eli Lilly. Other companies are developing new drugs to break into the market. This piece is a concise overview of companies creating and testing new drugs, how far along they are, and what Novo Nordisk and Eli Lilly are doing to compete with these emerging rivals.

The popularity of new weight loss drugs has led to a diabetes treatment shortage

The FDA approved Ozempic to help patients with diabetes, but the popularity of semaglutide as a weight loss drug led doctors to prescribe Ozempic to nondiabetic patients who needed to lose weight. Ozempic became so popular that manufacturers could not keep pace with demand, posing risks for Ozempic-users with diabetes.

The pancreas releases digestive enzymes and regulates blood sugar

The pancreas weighs about the same as a deck of cards and is smaller than the average adult human hand. This lopsided glandular organ controls blood sugar levels through insulin production and helps the body digest food by creating a neutralizing tonic filled with digestive enzymes.

Weight Watchers began offering access to GLP-1 weight-loss medications in 2023 after losing more than 1.5 million members over the previous two years.

How weight loss drugs could reduce obesity costs

A detailed analysis from finance giant ING finds semaglutide and other weight loss drugs could significantly drive down global costs stemming from heart disease and other health problems associated with obesity. The benefits will vary, depending on each country’s demographics and drug and healthcare costs.

Neural replays in mice help explain food aversions

Princeton University scientists published research in 2025 analyzing how mice learn to associate certain foods or flavors with feeling ill—even when there’s a time gap between eating something and feeling sick. The work, performed with grape Kool-Aid and injections of a substance that made mice sick, traced the literal “gut reaction” of how gut distress signals are linked to neural replays of what the mouse ate.

Aspartame was a surprise discovery from a lab working on gastric ulcers

As with saccharin and cyclamate, the aspartame discovery arose from its discoverer tasting something sweet from his workplace. In 1965, American chemist James Schlatter licked a white powder off his finger as he picked up a piece of paper and was startled to discover it tasted sweet. He applied for a patent for the substance, and received it in 1970. It is now one of the most popular artificial sweeteners. (Some users may experience a paywall.)

Hormone and peptide compounds imported from China soared in 2025

US customs data indicates that these imports doubled to $328M in the first three quarters of 2025, from $164M in the same period of 2024. The imports include GLPs, among other products. (Some users may experience a paywall.)

Multiple sugar substitutes were accidental discoveries when lab workers didn't wash their hands

Saccharin, aspartame, and cyclamate all have origin stories from lab workers tasting something sweet on their hands. A Johns Hopkins University worker in the late 1800s, for example, tasted something sweet on his (unwashed or poorly washed) hands during dinner, prompting him to then taste everything on his lab bench in order to identify that the sweetness was a compound derived from his overheated coal tar—a substance he later named saccharin. (Some users may encounter a paywall.)

Pharmaceutical companies can use ChatGPT to improve drug development

Moderna has incorporated the tool into its workflows to accelerate analysis and identify optimal drug dosage from clinical data. The company's legal team also uses a custom GPT—Contract Companion—to break down and summarize contracts quickly.

Alpha-gal allergy is a problem for red meat lovers, and that same sugar is an issue for xenotransplants, too

In recent years, researchers have discovered ticks can induce spontaneous meat allergies in people they bite, a particularly problematic condition for previous meat lovers. This 18-minute podcast from RadioLab breaks down the cause.

New drugs called Gepants have been shown to improve the quality of life of many sufferers.

Journalist Eva Wiseman has had migraines since childhood. Beginning with a yawn they segue into visual auras before turning into severe pain. As it so happened, she experienced a migraine during the course of her interview with Dr. Peter Goadsby, a pioneer in understanding and treating migraines as well as getting the world to treat them seriously.

Type 1.5 diabetes is typically found in adulthood

Clinically referred to as latent autoimmune diabetes in adults, or LADA, this condition is often diagnosed as Type 2 diabetes. However, it’s an autoimmune disease that eventually requires insulin, just like Type 1 diabetes. Misdiagnosis can result in uncontrolled high blood sugar and a slew of other serious health issues.

Gut microbiome rewrites may help reduce allergies

Researchers are investigating different strategies to determine if one day they could give people a combination of gut microbes to set them up for fewer allergies. In animal research, scientists have already prevented severe allergic responses in allergy-prone mice—supplying them with gut microbes from healthy, non-allergic human babies.

Cats have a mutation preventing them from tasting sugar

When certain tastes (sweet, umami, bitter) become irrelevant due to a species' diet or lifestyle, the genes for those tastes degrade. In felines, scientists believe a shift to a protein-heavy diet put evolutionary pressure on the genes responsible for tasting sweetness. (Some users may encounter a paywall.)

The US FDA defines peptides as being 40 amino acids or less

The US Food and Drug Administration regulates these short strings of amino acids as drugs and approves them for commercial use. These products may be produced naturally or synthesized via medicinal chemistry for therapeutic use.

How scientists are using molecules found in acidophiles to develop new medical treatments

The Berkeley Pit, an open-pit copper mine in Butte, Montana, that ceased operations in 1982 and is now filled with highly acidic water, is home to various species of fungi and yeast. These extremophiles produce unique compounds that may have anti-inflammatory benefits and have already been used to create an antibiotic for staph infections.

Even in recent history, adaptations to the environment drove human evolution

Through genetics, environmental pressures, and cultural influences, humans have evolved to tolerate lactose, develop varying skin pigmentation, and acquire genetic resistance to diseases like bubonic plague. The metabolic and digestive systems of Indigenous peoples have adapted to their diet, which is influenced by the availability of food and water.

The dark side of modern sugar production

Humanity's ancestors evolved to wring more calories from sugary fruits by storing excess sugar as fat, an adaption that's culminated in many peoples' palettes preferring calorie-rich sweet. Now, the desire for sugar has both contributed to a widespread health crisis and been at the center of atrocities around the world.

Hookworm infection, though risky, may help fight certain health conditions

Early clinical trial research suggests that the parasites trigger the production of specific proteins that quiet our immune systems. This keeps the parasites from being killed, but it also quiets the inflammatory response that underpins allergies, type 2 diabetes, celiac disease, and other autoimmune conditions. Researchers still caution that infection with too many hookworms can cause serious medical complications and that this is not a standardized or approved medical treatment.

Research suggests Ozempic has benefits beyond weight loss

Semaglutide, the key ingredient in Ozempic, is proving to be more than just a diabetes and weight loss drug. Research suggests it may also help prevent strokes, improve heart health, and slow Alzheimer’s.

Gestational diabetes occurs when the body can't produce insulin during pregnancy

Globally, pregnant people are increasingly at risk to develop gestational diabetes due to rising maternal ages and obesity rates. The condition is associated with heavier fetal weight, congenital abnormalities, and perinatal mortality, which includes stillbirths and deaths of babies younger than 7 days old.

GMOs sound scary, but you eat them every day

Why are GMOs bad? They aren’t. We’ve been eating them for decades with no ill effects, which makes sense, because a genetically modified organism is simply an organism, like every other organism, produces hundreds of thousands of proteins, but one or two of them are proteins that were chosen specifically by humans. Watch this 11-minute video for more.

Listen to how the 1902 'poison squad' experiments changed food safety in America

As part of government research, a group of young men were paid to eat standard American food—replete with food additives like borax and formaldehyde—which revealed the dangers of unregulated food. The work was led by the first FDA commissioner, Harvey Wiley, who helped end the "century of the great stomachache."